- Home
- SLN vs CRMT Comparison
SLN vs CRMT Comparison
Compare SLN & CRMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- CRMT
- Stock Information
- Founded
- SLN 1994
- CRMT 1981
- Country
- SLN United Kingdom
- CRMT United States
- Employees
- SLN N/A
- CRMT N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- CRMT Other Specialty Stores
- Sector
- SLN Health Care
- CRMT Consumer Discretionary
- Exchange
- SLN Nasdaq
- CRMT Nasdaq
- Market Cap
- SLN 268.8M
- CRMT 284.5M
- IPO Year
- SLN N/A
- CRMT N/A
- Fundamental
- Price
- SLN $4.73
- CRMT $34.21
- Analyst Decision
- SLN Buy
- CRMT Buy
- Analyst Count
- SLN 5
- CRMT 1
- Target Price
- SLN $32.60
- CRMT $45.00
- AVG Volume (30 Days)
- SLN 50.2K
- CRMT 179.7K
- Earning Date
- SLN 11-13-2025
- CRMT 09-04-2025
- Dividend Yield
- SLN N/A
- CRMT N/A
- EPS Growth
- SLN N/A
- CRMT N/A
- EPS
- SLN N/A
- CRMT 1.61
- Revenue
- SLN $27,169,000.00
- CRMT $1,378,681,000.00
- Revenue This Year
- SLN N/A
- CRMT $6.23
- Revenue Next Year
- SLN N/A
- CRMT $5.10
- P/E Ratio
- SLN N/A
- CRMT $21.18
- Revenue Growth
- SLN 22.28
- CRMT 0.64
- 52 Week Low
- SLN $1.97
- CRMT $33.50
- 52 Week High
- SLN $20.48
- CRMT $62.72
- Technical
- Relative Strength Index (RSI)
- SLN 41.23
- CRMT 28.17
- Support Level
- SLN $4.77
- CRMT $33.50
- Resistance Level
- SLN $5.80
- CRMT $37.74
- Average True Range (ATR)
- SLN 0.36
- CRMT 1.86
- MACD
- SLN -0.03
- CRMT -0.70
- Stochastic Oscillator
- SLN 22.46
- CRMT 5.12
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About CRMT America's Car-Mart Inc
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.